Efgartigimod SC (VYVGART Hytrulo)

About Argenx

Argenx is a mission-driven immunology company dedicated to improving the lives of patients with severe autoimmune diseases through innovative antibody therapies. Its core achievement is the successful global commercialization of efgartigimod (VYVGART®), a first-in-class FcRn blocker, establishing a commercial foundation and validating its platform. The company's strategy centers on expanding efgartigimod's label into multiple autoimmune indications while advancing a broad, deep pipeline of novel candidates from its proprietary SIMPLE Antibody™ platform, aiming to build a leading, fully integrated immunology franchise.

Therapeutic Areas

Other Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs